First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer is a phase 1/2, interventional study registered as NCT07355205 by Washington University School of Medicine, with a registry enrolment figure of 26 participants, started 2026-07-07 and due to reach its primary completion in 2032-07-31. Interventions recorded: Ipilimumab; Nivolumab; Nogapendekin alfa inbakicept. Conditions listed: Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent. Primary outcome: Progression-free survival (PFS) (Phase Ib acceptable dose participants and Phase II participants); Incidence of dose-limiting toxicities (DLTs) (Phase Ib participants). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed, previously untreated or recurrent metastatic NSCLC". Sites: United States. No results are recorded here; the registry entry is the source.